BIO and PhRMA back Acorda in patent appeal

The Biotechnology Industry Organization (BIO) and the Pharmaceutical Research and Manufacturers of America (PhRMA), two trade groups representing US pharmaceutical companies, have backed Acorda in an appeal to the US Court of Appeals for the Federal Circuit.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Victory for Mylan and Teva as appeals court affirms invalidations

12 September 2018 Generic drug makers Mylan and Teva were afforded victory earlier this week when the US Court of Appeals for the Federal Circuit affirmed the invalidation of four patents owned by biotech company Acorda Therapeutics.

Americas

Four of Acorda’s Ampyra patents invalidated

3 April 2017 A Delaware district court has invalidated four patents owned by Acorda Therapeutics after the company and Alkermes Pharma Ireland alleged that Apotex, Mylan, Roxane Laboratories and Teva infringed them.

More features

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

BIO and PhRMA back Acorda in patent appeal

More on this story

Editor's picks

Editor's picks

More features